NCT06970847
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
Active, Not Recruiting
PHASE3Ages 18+InterventionalDiagnosticClarity Pharmaceuticals Ltd
~220 participants
Updated 2026-05-14 on ClinicalTrials.gov
What's tested:64Cu-SAR-bisPSMA
At a glance
Recruiting sites
0 of 22 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer
Measured over Up to 52 Weeks
Conditions
Where it's being run
22 sites across 16 statesCalifornia3
New South Wales3
Texas2
Utah2
Florida1
Illinois1
Indiana1
Louisiana1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancerUp to 52 Weeks
Co-primary endpoints of participant-level CDR and region level PPV assessed independently for Day 1 and Day 2: * Participant-level CDR, defined as the proportion of TP participants scan out of all participants * Region-level PPV, defined as the proportion of TP regions out of all positive regions.